-- Days : -- HRS : -- MIN : -- SEC

Be The First to Know

Opinion|Videos|January 17, 2024

Revumenib for Patients With Acute Myeloid Leukemia

Author(s)Rohit Gosain, MD, Rahul Gosain, MD, Uma Borate, MBBS

Medical oncologists discuss the results from the SAVE and AUGMENT-101 clinical trials investigating revumenib in patients with acute myeloid leukemia.

Episodes in this series

Rohit Gosain, MD; Rahul Gosain, MD; and Uma Borate, MBBS, presenting slides

EP. 1 TRANSFORM-1: Navitoclax and Ruxolitinib in Untreated Myelofibrosis

Rohit Gosain, MD; Rahul Gosain, MD; and Uma Borate, MBBS, presenting slides

EP. 2 MANIFEST-2: Pelabresib plus Ruxolitinib in JAK Inhibitor–Naïve Myelofibrosis

Rohit Gosain, MD; Rahul Gosain, MD; and Uma Borate, MBBS, presenting slides

EP. 3 Revumenib for Patients With Acute Myeloid Leukemia

Rohit Gosain, MD; Rahul Gosain, MD; and Uma Borate, MBBS, presenting slides

EP. 4 Key Takeaways from ASH 2023 in Myelofibrosis and AML

Newsletter

Stay up to date on practice-changing data in community practice.

Related to this article

Rusfertide Improves Hematocrit Control, Reduces Phlebotomy in Polycythemia Vera

October 21st, 2026

Rusfertide Improves Hematocrit Control, Reduces Phlebotomy in Polycythemia Vera

The phase 3 VERIFY trial found that rusfertide improved clinical response, reduced phlebotomy requirements, and eased symptom burden in patients with polycythemia vera receiving standard-of-care therapy.

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Insurance Delays and Travel Strain CAR T Referral in Early Relapsed Myeloma

NCCN Guidelines Add Cosibelimab for Locally Advanced CSCC

Real-World Data for Darolutamide vs Abiraterone Triplet Therapy in mHSPC

Oncologists Debate Role of On-Body Injector for Transplant-Ineligible Myeloma

Rusfertide Improves Hematocrit Control, Reduces Phlebotomy in Polycythemia Vera